Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Department of Pharmacology, Faculty of Pharmacy, Jouf University, Sakaka 2014, Saudi Arabia.
J Neuroimmunol. 2019 Dec 15;337:577062. doi: 10.1016/j.jneuroim.2019.577062. Epub 2019 Sep 6.
Interleukins (ILs)-22, 32α and 34 were monitored in the sera of relapsing-remitting multiple sclerosis (RRMS) patients at different time intervals with or without interferon β-1b, interferon β-1a and fingolimod treatments. The results showed that sera of untreated RRMS patients were statistically higher in concentration of IL-22 (P < .001), but not IL-32α and IL-34, than those of healthy individuals. Interestingly, interferon β-1b, interferon β-1a and fingolimod treatments led to a significant decrease of serum concentrations of ILs-22 and 32α, but not 34, at 6 and 12 months of treatment, compared to their initial concentrations before initiating therapy. The correlation analysis revealed that the changes of serum IL-22 (r = 0.814) and, to a lesser extent, IL-32α (r = 0.381) concentrations were positively correlated with those of expanded disability status score. In conclusion, serum IL-22 concentration may be a potential marker for MS disease severity and efficacy of treatment.
白细胞介素 (ILs)-22、32α 和 34 在复发缓解型多发性硬化症 (RRMS) 患者的血清中被监测，这些患者在不同时间间隔内接受了干扰素 β-1b、干扰素 β-1a 和芬戈莫德治疗。结果表明，未经治疗的 RRMS 患者血清中白细胞介素 -22 (IL-22) 的浓度明显高于健康个体 (P<.001)，但白细胞介素 -32α 和白细胞介素 -34 则不然。有趣的是，干扰素 β-1b、干扰素 β-1a 和芬戈莫德治疗在治疗 6 个月和 12 个月时导致血清中白细胞介素 -22 和 32α 的浓度显著下降，但白细胞介素 -34 则不然，与治疗前的初始浓度相比。相关性分析表明，血清白细胞介素 -22 (r=0.814) 和白细胞介素 -32α(r=0.381) 浓度的变化与扩展残疾状况评分的变化呈正相关。总之，血清白细胞介素 -22 浓度可能是 MS 疾病严重程度和治疗效果的潜在标志物。
